18 news items
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
BMY
10 May 24
common types of lung cancer, representing up to 84% of diagnoses. Non-metastatic cases account for the majority of NSCLC diagnoses (approximately 60
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY
26 Apr 24
the ureters and renal pelvis. The majority of urothelial carcinomas are diagnosed at an early stage, but approximately 50% of patients who undergo surgery
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY
25 Apr 24
Initiative to Deliver ~$1.5 Billion in Cost Savings, the Majority of Which Will be Reinvested to Fund Innovation and Drive Growth
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
AAL
AZN
BA
25 Apr 24
. “This is all in-line with our 2024 outlook that suggests the major equity indices are overvalued while the best opportunities are likely beneath
Market Whales and Their Recent Bets on BMY Options
BMY
15 Apr 24
Range
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between
fcrnoei834m3whouhuh0o7w67b1aapbisujdblmqk0ak
AGEN
BMY
12 Apr 24
this year and plans to present detailed Phase 2 efficacy results, including response durability and updated Phase 1 survival data, at a major medical
lbhv6
BMY
JNJ
MRK
10 Apr 24
. Already present across major European markets, Mainz Biomed continues to expand the international commercialization of ColoAlert®
vlub6e82hjlyowcjvns3qc3hnbhvb38o0gpqd18z8p3uff1gg
BMY
8 Apr 24
experienced stability or improvements in key metabolic parameters over 52 weeks of treatment.
The majority of patients (65%) experienced
0x3u 753vu1iah2r
BMY
TSVT
5 Apr 24
showed a significant improvement in overall response rates (p<0.0001) with the majority (71%) of patients treated
dqlnpi5w6hr0j9zdpxw3gd7s
BMY
25 Mar 24
received ELIQUIS had a statistically significant lower risk of stroke/systemic embolism (S/SE) and major bleeding (MB) than those patients who received
49ibeec97bzwjclefri2pig69gqysbfhhnmrr2h7cj77dp22 ti4ogkf
BMY
20 Mar 24
rate (ORR) with the majority (71.3% [95% CI: 65.7-76.8]) of patients treated with Abecma achieving
l96q56abmii7i0b1zyw3g
BMY
7 Mar 24
.2 The majority of urothelial carcinomas are diagnosed at an early stage, but approximately 50% of patients who undergo
- Prev
- 1
- Next